Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422.SZ)
Chengdu, AH, CN
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.85% | +8.34% | +6.66% | +19.09% | +5.67% | +23.92% | -4.16% | +11.05% | +63.61% | +153.98% | +143.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | -1 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-15.9% Q1'26: -3.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-42.5% Q1'26: -21.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+2.8% Q1'26: -3.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+11.0% ★ Q1'26: +6.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+6.2% ★ Q1'26: +4.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.8% ★ Q1'26: -0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.27× ★ Q1'26: 3.78× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 1 EPS Ana. |
Dec 2027 8 Rev. Ana. 2 EPS Ana. |
Dec 2028 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.76B
est: 8.24B (-5.8%)
|
8.57B
est: 8.25B (+3.8%)
|
11.43B
est: 10.90B (+4.9%)
|
16.35B
est: 15.93B (+2.6%)
|
17.64B
est: 17.62B (+0.1%)
|
16.46B
est: 16.02B (+2.8%)
|
17.28B
est: 17.43B (-0.9%)
|
19.04B
est: 19.45B (-2.1%)
|
21.45B
est: 21.34B (+0.5%)
|
21.81B
est: 22.89B (-4.7%)
|
18.35B
est: 18.03B (+1.8%)
|
20.28B
19.50B – 20.88B
+12.5% YoY
|
22.88B
20.16B – 25.61B
+12.8% YoY
|
25.90B
23.82B – 27.88B
+13.2% YoY
|
| EBITDA |
1.61B
est: 1.54B (+4.3%)
|
1.65B
est: 1.54B (+6.8%)
|
1.93B
est: 2.04B (-5.1%)
|
2.82B
est: 2.98B (-5.4%)
|
2.77B
est: 3.29B (-16.0%)
|
2.38B
est: 2.99B (-20.6%)
|
2.69B
est: 3.26B (-17.4%)
|
3.42B
est: 3.63B (-6.0%)
|
4.60B
est: 3.99B (+15.3%)
|
5.25B
est: 5.66B (-7.2%)
|
3.43B
est: 4.46B (-22.9%)
|
5.01B
4.82B – 5.16B
+12.5% YoY
|
5.65B
4.98B – 6.33B
+12.8% YoY
|
6.40B
5.89B – 6.89B
+13.2% YoY
|
| EBIT |
1.04B
est: 1.03B (+1.0%)
|
995.63M
est: 1.03B (-3.2%)
|
1.13B
est: 1.36B (-16.7%)
|
1.83B
est: 1.98B (-7.9%)
|
1.69B
est: 2.20B (-22.8%)
|
1.22B
est: 2.00B (-38.8%)
|
1.48B
est: 2.17B (-31.6%)
|
2.26B
est: 2.42B (-6.7%)
|
3.41B
est: 2.66B (+28.2%)
|
4.04B
est: 3.81B (+6.2%)
|
2.01B
est: 3.00B (-32.9%)
|
3.37B
3.24B – 3.47B
+12.5% YoY
|
3.81B
3.35B – 4.26B
+12.8% YoY
|
4.31B
3.96B – 4.64B
+13.2% YoY
|
| Net Income |
645.27M
est: 883.92M (-27.0%)
|
584.64M
est: 773.43M (-24.4%)
|
748.54M
est: 741.87M (+0.9%)
|
1.21B
est: 1.34B (-9.6%)
|
937.86M
est: 1.16B (-18.9%)
|
829.39M
est: 920.75M (-9.9%)
|
1.10B
est: 1.21B (-9.0%)
|
1.71B
est: 1.82B (-6.4%)
|
2.46B
est: 2.51B (-2.0%)
|
2.94B
est: 2.96B (-1.0%)
|
1.70B
est: 1.71B (-0.3%)
|
2.12B
1.90B – 2.33B
+24.0% YoY
|
2.56B
2.49B – 2.62B
+20.7% YoY
|
3.13B
2.80B – 3.44B
+22.5% YoY
|
| SGA |
2.06B
est: 2.12B (-3.3%)
|
2.50B
est: 2.13B (+17.5%)
|
3.20B
est: 2.81B (+13.8%)
|
6.84B
est: 4.11B (+66.4%)
|
6.76B
est: 4.55B (+48.8%)
|
5.18B
est: 4.13B (+25.3%)
|
5.34B
est: 4.50B (+18.8%)
|
5.00B
est: 5.02B (-0.4%)
|
4.83B
est: 5.50B (-12.2%)
|
3.89B
est: 5.50B (-29.2%)
|
4.13B
est: 4.33B (-4.5%)
|
4.87B
4.68B – 5.01B
+12.5% YoY
|
5.49B
4.84B – 6.15B
+12.8% YoY
|
6.22B
5.72B – 6.69B
+13.2% YoY
|
| EPS |
0.45
est: 0.56 (-19.6%)
|
0.41
est: 0.49 (-16.3%)
|
0.52
est: 0.47 (+10.6%)
|
0.85
est: 0.85 (+0.0%)
|
0.66
est: 0.73 (-9.9%)
|
0.58
est: 0.58 (-0.6%)
|
0.78
est: 0.77 (+1.6%)
|
1.22
est: 1.15 (+5.7%)
|
1.69
est: 1.59 (+6.4%)
|
1.86
est: 1.86 (-0.2%)
|
1.07
est: 1.07 (-0.3%)
|
1.33
1.19 – 1.46
+24.0% YoY
|
1.61
1.57 – 1.65
+20.7% YoY
|
1.97
1.76 – 2.16
+22.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares MSCI All China Health Care Index ETF KURE | 1.75% | 1.39M | 0.79% |
| 2 | Xtrackers Harvest CSI 300 China A-Shares ETF ASHR | 0.19% | 2.53M | 0.65% |
| 3 | Xtrackers Harvest CSI300 UCITS ETF 1D ASHR.L | 0.17% | 525.8K | 0.65% |
| 4 | HSBC MSCI China A UCITS ETF HMCT.L | 0.16% | 217.3K | 0.30% |
| 5 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.15% | 23.9K | 0.65% |
| 6 | iShares MSCI China A ETF CNYA | 0.14% | 331.5K | 0.60% |
| 7 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.14% | 196.9K | 0.35% |
| 8 | iShares MSCI China A UCITS ETF CNYA.L | 0.14% | 4.18M | 0.40% |
| 9 | iShares MSCI China A UCITS ETF CNYE.MI | 0.14% | 138.0K | 0.45% |
| 10 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.13% | 498.0K | 0.44% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Deguang Chen | Officer | — | male |
| Degui Lai | Chief Financial Officer & Deputy GM | — | male |
| Hao Feng | Deputy GM & Secretary of the Board of Directors | — | male |
| Lanlan Li | Sales Manager | — | — |
| Sichuan Liu | GM & Director | — | male |
| Tan Hongbo | Deputy General Manager | — | male |
| Yi Feng | Deputy GM & Chief Strategy Officer | — | male |
| Yihong Liao | Deputy General Manager | — | female |
| Zhonghua Wu | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002422.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
